Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Assets (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Assets data on record, last reported at $808.1 million in Q4 2025.

  • For Q4 2025, Assets rose 76.46% year-over-year to $808.1 million; the TTM value through Dec 2025 reached $808.1 million, up 76.46%, while the annual FY2025 figure was $808.1 million, 76.46% up from the prior year.
  • Assets reached $808.1 million in Q4 2025 per OCUL's latest filing, up from $410.9 million in the prior quarter.
  • Across five years, Assets topped out at $808.1 million in Q4 2025 and bottomed at $122.6 million in Q2 2023.
  • Average Assets over 5 years is $315.6 million, with a median of $236.9 million recorded in 2021.
  • Peak YoY movement for Assets: crashed 31.47% in 2023, then soared 321.92% in 2024.
  • A 5-year view of Assets shows it stood at $204.9 million in 2021, then fell by 27.14% to $149.3 million in 2022, then soared by 68.84% to $252.1 million in 2023, then surged by 81.68% to $457.9 million in 2024, then skyrocketed by 76.46% to $808.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $808.1 million in Q4 2025, $410.9 million in Q3 2025, and $451.3 million in Q2 2025.